Moderna MRNA 深 滬
等待開盤 03-26 09:30:00 美东时间
53.54
+2.200
+4.29%
華盛通- 最 高54.24
- 今 開52.57
- 成交量 446.78万股
- 最 低 52.53
- 昨 收 51.34
- 總市值 211.45亿
- 52周最高 59.55
- 市盈率 靜 --
- 換手率 1.13%
- 52周最低 22.28
- 委 比 -97.67%
- 總股本 3.95亿
- 歷史最高 497.49
- 量 比 0.59
- 振 幅 3.33%
- 歷史最低 11.54
- 每 手 1
- 風險率 8.86%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多White House misses deadline for CDC director nominee
The Trump administration has failed to provide a nominee to become permanent director of the CDC despite a Wednesday deadline. The delay means that National Institutes of Health chief Jay Bhattacharya...
今天 04:24
Roivant Sciences files Form 8-K/A to add Moderna settlement agreement exhibit
Roivant Sciences files Form 8-K/A to add Moderna settlement agreement exhibit Roivant filed an amended Form 8-K to correct its earlier report by filing the Settlement Agreement as an exhibit. The amendment relates to a March 3, 2026 settlement between Genevant and Arbutus and Moderna that resolves p
03-23 20:44
期权扫描 | 多张看跌期权涨超2000%！超微电脑期权成交激增超4倍；SoFi 再放量，看涨期权占比超65%
多张看跌期权涨超2000%！超微电脑期权成交激增超4倍；SoFi 再放量，看涨期权占比超65%；英特尔期权成交翻倍，先进封装工厂将于年内投产>>
03-23 20:10
Trump administration reportedly shortlisting CDC nominees
Two physicians with somewhat contrasting views on vaccines are among the potential candidates the Trump administration is considering as its pick to lead the U.S. Centers for Disease Control and Preve...
03-22 00:24
Medicare Chief Chris Klomp Optimistic On CDC Director Search As Vaccine Fight Roils Agency— 'We Will Select...'
Medicare Chief Chris Klomp is optimistic for strong outcome in the search of CDC leader in midst of legal and institutional turbulence over vaccine policy.
03-20 19:18
Federal Judge Flags Legal Flaws In RFK Jr.'s Vaccine Overhaul
A federal judge warns that RFK Jr.'s vaccine overhaul likely violates federal law. Discover the latest on the ACIP legal challenge here.
03-17 19:19
REFILE-CytomX posts 2025 loss as revenue falls bigger-than-expected 45%
REFILE-CytomX posts 2025 loss as revenue falls bigger-than-expected 45% Removes extraneous word in second bullet of Overview section Overview US oncology biopharma's 2025 revenue fell about 45% and missed analyst expectations Company posted a net loss for 2025 as decline in operating expenses was no
03-16 19:16
CytomX FY2025 revenue fell 44.82% to USD 76.2 million
CytomX FY2025 revenue fell 44.82% to USD 76.2 million CytomX published a press release reporting full-year 2025 financial results and a business update. Total revenue was USD 76.2 million, down 44.8%, driven primarily by completion of performance obligations in the Bristol Myers Squibb collaboration
03-16 19:06
CytomX Therapeutics Announces 2025 Financial Results and Provides Business Update
CytomX Therapeutics, Inc. announced positive Phase 1 data for Varseta-M in advanced colorectal cancer and plans to align with the FDA on a potential registrational trial design in late-line CRC by mid-2026. Additional Phase 1 data is expected at major medical meetings in 2026. The company also initiated a Phase 1 combination study of Varseta-M with bevacizumab and plans a Phase 1b/2 study in combination with chemotherapy by end-2026. For CX-801, ...
03-16 11:05
